Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
NovoSeven for Joint Bleeds in Haemophilia with Inhibitors
NCT00571584Phase 4Completed
- Sponsor
- Novo Nordisk
- Start
- Nov 2002
- Primary completion
- Mar 2004
- Modality
- Recombinant Proteins and Enzymes
- Countries
- 7
01
Overview
Phase 4, randomised, double-blind trial of coagulation factor VIIa in hemophilia A and hemophilia B (HB) (2 arms), sponsored by Novo Nordisk. Primary endpoint: Global treatment response. Started Nov 2002; status: completed.
02
Drugs
coagulation factor VIIa
03
Conditions
hemophilia Ahemophilia B (HB)
Beyond the preview
Go deeper on NCT00571584.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00571584.